protein
degrad
proteasom
multicatalyt
proteinas
complex
centr
up
pathway
fig
pharmacolog
inhibit
origin
consid
lethal
cell
type
therefor
rather
surpris
bortezomib
velcad
approv
treatment
multipl
myeloma
ref
sinc
bortezomib
also
approv
treatment
mantl
cell
lymphoma
ref
recent
deriv
develop
variou
stage
clinic
trial
carfizomib
phase
iii
relaps
multipl
myeloma
phase
phase
natur
product
phase
ref
fig
ubistatin
also
discov
inhibit
proteasom
proteolysi
interf
recognit
polyubiquitin
chain
proteasom
ref
addit
natur
product
potenti
anticanc
properti
characteris
interfer
proteasom
proteolysi
review
ref
celastrol
ref
catechin
compon
green
tea
ref
disulfiram
combin
copper
ref
triterpenoid
inhibitor
ref
curcumin
ref
inhibit
homodim
format
proteasom
assembl
factor
ref
mani
natur
product
intrins
antitumour
properti
although
clear
whether
sole
attribut
proteasom
inhibitori
capac
instanc
statin
pleiotrop
effect
use
treat
varieti
differ
diseas
includ
prevent
cardiovascular
event
although
entir
clear
whether
due
direct
indirect
interfer
proteasom
proteolysi
ref
expect
proteasom
inhibit
caus
side
effect
peripher
neuropathi
myelosuppress
nausea
hypersens
increas
suscept
infect
ref
one
problem
proteasom
inhibitor
emerg
resist
howev
combin
sever
proteasom
inhibitor
exert
complementari
specif
appear
overcom
problem
resist
might
ad
benefit
enabl
reduc
dose
individu
drug
ref
altern
way
circumv
gener
toxic
compound
develop
inhibitor
select
immunoproteasom
ref
immunoproteasom
predominantli
express
bcell
tcell
macrophag
dendrit
cell
cell
type
haematopoiet
lineag
induc
cell
exposur
tumour
necrosi
factor
lead
exchang
catalyt
therebi
enhanc
antigen
present
preserv
cell
viabil
inflammationinduc
oxid
stress
ref
base
observ
immunoproteasom
promot
enhanc
antigen
process
present
predict
immunoproteasom
inhibitor
may
immunomodulatori
effect
attenu
autoimmunerel
patholog
inde
select
immunoproteasom
inhibitor
shown
prevent
experiment
coliti
ref
interfer
arthriti
mous
model
ref
strategi
appear
less
toxic
particularli
promis
treat
autoimmun
disord
might
extend
target
thymoproteasom
subform
express
thymu
ref
also
known
herp
viru
associ
usp
hausp
critic
cancer
progress
destabilis
effect
tumour
suppressor
ref
preferenti
deubiquityl
ligas
bind
partner
hdmx
result
destabilis
repress
transactiv
activ
ref
addit
substrat
includ
claspin
pten
ref
thu
exert
effect
control
cell
prolifer
apoptosi
make
attract
target
pharmaceut
intervent
ref
recent
highthroughput
screen
identifi
smallmolecul
compound
hbx
uncompetit
revers
inhibitor
fig
hbx
fig
compound
functionalis
cyanoindenopyrazin
deriv
inhibit
sever
dub
includ
stabilis
nongenotox
manner
result
induct
apoptosi
ref
independ
screen
recent
identifi
compound
analogu
fig
compound
inhibitor
vitro
live
cell
ref
proof
concept
cell
demonstr
stabilis
induct
repres
compound
seri
ref
function
key
role
regul
receptor
endocytosi
traffick
ubpi
interact
number
clinic
relev
cancer
target
includ
epiderm
growth
factor
receptor
egfr
ref
knockdown
result
accumul
ubiquityl
egfr
endosom
ref
hybrigen
report
identif
inhibitor
hbx
fig
compound
howev
clinic
use
inhibitor
question
follow
report
condit
knockout
adult
mice
result
liver
failur
probabl
result
pronounc
decreas
receptor
tyrosin
kinas
egfr
ref
prostaglandin
also
report
inhibitori
activ
dub
cellular
assay
famili
compound
form
group
lipid
deriv
serv
signal
molecul
affect
divers
protein
function
depend
localis
physiolog
context
prostaglandin
characteris
import
messeng
inflamm
ref
immun
respons
ref
emerg
role
cancer
jseri
prostaglandin
known
promot
apoptosi
fashion
ref
shown
inhibit
ubiquitin
isopeptidas
activ
cell
lysat
owe
presenc
crossconjug
keton
structur
fig
similarli
compound
unrel
prostaglandin
also
contain
crossconjug
keton
access
also
inhibit
isopeptidas
activ
contrast
aseri
prostaglandin
contain
singl
keton
less
efficaci
ubiquitin
isopeptidas
inhibitor
ref
henc
mechan
inhibit
jseri
prostaglandin
like
base
nucleophil
addit
dub
thiol
endocycl
compound
electrophil
access
prostaglandin
result
conjug
inhibitori
effect
prostaglandin
exemplifi
fig
compound
inhibit
activ
ref
ref
fig
detriment
effect
structur
therefor
perturb
activ
offer
possibl
interf
progress
parkinson
diseas
associ
mutat
ref
punaglandin
cyclopentadienon
cyclopentenon
prostaglandin
chlorin
endocycl
posit
compound
origin
isol
telesto
riisei
coral
exhibit
antiinflammatori
antitumour
activ
ref
higher
cytotox
effect
cell
jseri
prostaglandin
interestingli
effect
apoptosi
independ
ref
consist
punaglandin
punaglandin
also
potent
inhibitor
cellular
dub
activ
jseri
prostaglandin
propos
mechan
enhanc
inhibitor
activ
presenc
electroneg
cl
substitu
carbonyl
increas
reactiv
toward
nucleophil
addit
dub
catalyt
cystein
thiol
group
chlorin
lipid
could
therefor
repres
new
class
cancer
therapeut
ref
inhibitor
base
molecular
scaffold
preferenti
specif
toward
uch
also
report
instanc
stein
colleagu
report
discoveri
isatin
oacyl
oxim
fig
compound
inhibitori
activ
ref
recent
group
report
second
seri
inhibitor
base
pyridon
scaffold
ref
author
specul
compound
might
potenti
treatment
neurodegen
condit
ht
smallmolecul
compound
found
select
inhibitor
dub
associ
proteasom
block
degrad
ubiquityl
substrat
cellular
data
confirm
hypothesi
inhibit
indirectli
acceler
proteasom
degrad
protein
tau
involv
neurodegen
diseas
ref
mani
neurodegen
disord
parkinson
diseas
diseas
associ
accumul
misfold
protein
fig
compound
smallmolecul
inhibitor
could
potenti
use
elimin
toxic
protein
improv
prognosi
neurodegen
diseas
support
previous
link
neurodegen
diseas
loss
lead
atax
neurolog
phenotyp
mice
ref
degrasyn
deriv
smallmolecul
compound
block
janusactiv
kinas
activ
cell
treatment
induc
accumul
polyubiquityl
conjug
phenomenon
attribut
inhibitori
activ
toward
sever
dub
includ
ref
might
therapeut
valu
proapoptot
properti
recent
describ
ref
support
treatment
cell
result
modul
anti
proapoptot
protein
ref
work
suggest
could
administ
bortezomib
combin
result
synergist
inhibit
tumour
cell
regul
apoptosi
prolong
surviv
anim
ref
recent
addit
broadspecif
dub
inhibitor
fig
compound
discov
use
report
technolog
ref
given
broad
specif
util
probabl
lie
role
tool
recov
ubiquityl
protein
cellfre
cellular
experiment
system
virus
also
encod
dub
target
block
viral
infect
papainlik
proteas
plpro
dub
encod
sever
acut
respiratori
syndrom
coronaviru
sarscov
ref
plpro
block
antivir
respons
indic
relev
key
infecti
process
viral
evas
host
innat
immun
respons
noncoval
inhibitor
plpro
fig
compound
block
sarscov
viral
replic
without
measur
cytotox
effect
henc
promis
antivir
drug
candid
induc
conform
chang
plpro
effect
inactiv
dub
profil
dub
activ
cell
expos
use
ubiquitinspecif
activesit
probe
demonstr
inhibitor
select
plpro
might
explain
low
cytotox
ref
summari
studi
illustr
potenti
mani
dub
suitabl
drug
target
sever
challeng
remain
recent
develop
novel
discoveri
platform
enzym
substrat
multiubiquitin
chain
differ
type
length
chop
report
technolog
isopeptidebondbas
assay
use
identifi
novel
dub
inhibitor
greater
specif
sensit
provid
framework
optimis
suitabl
drug
fig
compound
belong
class
tetrasubstitut
imidazolin
potent
nonpeptid
antagonist
act
competit
inhibitor
block
interact
ref
consequ
stabilis
substrat
noxa
contribut
increas
apoptosi
cell
cycl
arrest
phase
antitumour
properti
demonstr
cancer
cell
express
wildtyp
ref
effici
elimin
tumour
xenograft
mice
caus
measur
abnorm
anim
ref
preclin
studi
combin
proteasom
inhibitor
bortezomib
induc
addit
cytotox
malign
multipl
myeloma
cell
synergist
antitumour
activ
might
extend
clinic
applic
bortezomib
neoplasia
exhibit
reduc
sensit
proteasom
inhibitor
ref
analogu
current
phase
clinic
trial
treatment
solid
tumour
haematolog
malign
proofofconcept
data
provid
discoveri
nutlin
spur
addit
research
area
includ
identif
famili
compound
rita
fig
compound
also
target
ubiquitinligas
activ
result
activ
apoptosi
ref
addit
spirooxindol
exemplifi
fig
compound
chromenotriazolopyrimidin
also
report
effect
nonpeptidomimet
smallmolecul
inhibitor
interact
ref
anoth
mode
inhibit
block
associ
proteasom
fig
compound
one
first
compound
found
induc
level
tumour
cell
line
activ
transcript
activ
ref
current
investig
oral
agent
treatment
refractori
solid
tumour
clinic
trial
natur
product
also
import
sourc
novel
ligas
inhibitor
exampl
microbi
extract
deriv
ferment
microorgan
actinomycet
bacteria
fungi
screen
discov
new
compound
antagonis
interact
among
chlorofusin
fig
compound
fungal
metabolit
isol
fusarium
sp
found
highest
inhibitori
activ
toward
ref
chlorofusin
nineresidu
cyclic
peptid
contain
lornithin
side
chain
link
highli
functionalis
tricycl
chromophor
studi
establish
neither
cyclic
peptid
chromophor
chlorofusin
alon
simpl
deriv
thereof
account
inhibit
interact
whole
structur
chlorofusin
requir
ref
second
exampl
natur
product
exhibit
inhibit
interact
enantiom
hexylitacon
acid
isol
cultur
marinespongederiv
fungu
arthrinium
sp
ref
hexylitacon
acid
impair
interact
dosedepend
manner
deriv
includ
monomethyl
ester
dihydro
deriv
dihydro
deriv
monomethyl
ester
show
inhibitori
activ
chalcon
aromat
keton
previous
characteris
potenti
antitumourigen
therapeut
ovarian
cancer
ref
gastric
cancer
tumour
ref
chalcon
deriv
interfer
interact
bind
near
tryptophanbind
pocket
hydrophob
cleft
ref
molecular
model
studi
indic
boron
acid
bind
lysin
residu
ref
detail
mechan
cytotox
activ
chalcon
remain
determin
case
enhanc
apoptosi
relat
inhibit
proteasom
thu
stabilis
exemplifi
boron
chalcon
deriv
fig
compound
ref
regardless
seem
like
chalconemedi
inhibit
interact
contributori
mechan
report
antitumour
properti
ref
ubiquitin
ligas
constitut
potenti
therapeut
target
scf
sphase
kinaseassoci
protein
ubiquitin
ligas
contain
fbox
protein
determin
substrat
specif
upregul
associ
decreas
level
neg
correl
good
prognosi
cancer
ref
therefor
compound
directli
target
repres
potenti
drug
cancer
therapi
use
ht
chen
colleagu
identifi
compound
cpda
promis
inhibitor
prevent
incorpor
fbox
protein
ligas
complex
cpda
thu
lead
ubiquitindepend
accumul
substrat
ligas
activ
consequ
induc
cell
cycl
arrest
apoptosi
notabl
cpda
work
synergist
proteasom
inhibitor
bortezomib
ref
probabl
interf
neddyl
recent
two
addit
exampl
inhibitor
report
first
use
fluoresc
polaris
screen
biplanar
dicarboxyl
acid
compound
shown
alloster
inhibitor
substrat
recognit
yeast
fbox
protein
degrad
mani
substrat
phosphorylationdepend
manner
inhibitor
perturb
phosphodegron
bind
pocket
ref
second
group
use
yeastbas
chemic
genet
screen
identifi
modul
activ
ref
biochem
studi
confirm
specif
inhibit
ubiquityl
transcript
factor
reduc
bind
probabl
due
direct
bind
cereblon
crbn
damag
dnabind
protein
form
ligas
complex
import
embryon
develop
complex
target
thalidomid
fig
compound
clinic
approv
drug
treatment
multipl
myeloma
leprosi
inflammatori
bowel
diseas
crohn
diseas
ref
one
enantiom
thalidomid
found
teratogen
side
effect
bind
thalidomid
crbn
complex
inhibit
crbn
ligas
activ
appear
underli
molecular
mechan
thalidomideinduc
teratogen
perturb
embryon
develop
ref
key
effector
enzym
muscular
atrophi
area
unmet
medic
need
sever
differ
patholog
ref
use
elisabas
ht
platform
progenra
identifi
novel
modul
ubiquitin
ligas
inhibit
autoubiquityl
myosin
heavychain
ubiquityl
protect
myotub
dexamethasoneinduc
muscl
wast
ref
outlin
identifi
ligas
inhibitor
direct
toward
interact
druggabl
therefor
challeng
complex
enzym
famili
lack
detail
precis
molecular
mechan
fact
reli
interact
mediat
activ
make
design
ligas
inhibitor
difficult
ref
potenti
offer
framework
translat
applic
interf
mani
differ
biolog
process
highli
specif
manner
recent
report
identif
specif
scf
inhibitor
increas
confid
possibl
develop
inhibitor
emerg
class
import
drug
target
ubiquitin
conjug
requir
initi
activ
ubiquitin
enzym
adenyl
ctermin
carboxyl
group
ubiquitin
form
highenergi
ubiquitin
adenyl
intermedi
follow
format
thiol
ester
carboxyl
group
ubiquitin
thiol
group
seri
reaction
activ
cterminu
ubiquitin
subsequ
nucleophil
attack
ref
block
reaction
could
therefor
use
inhibit
ubiquitin
conjug
vitro
studi
suggest
knockdown
ligas
result
lower
level
protein
ubiquityl
eventu
induc
cell
death
malign
cell
ref
identifi
novel
inhibitor
yang
colleagu
screen
librari
small
compound
identifi
benzoic
acid
ethyl
ester
first
cellperm
inhibitor
effici
reduc
bulk
protein
ubiquityl
sumoyl
prevent
degrad
contribut
enhanc
apoptosi
also
attenu
cytokinemedi
nuclear
activ
regul
proteasom
degrad
inhibitori
subunit
function
probabl
bind
irrevers
activesit
cystein
ligas
therefor
prevent
ubiquitin
transfer
ref
howev
compound
also
target
sever
dub
includ
crosslink
kinas
antitumour
activ
anim
ref
fig
compound
anoth
smallmolecul
inhibitor
shown
interfer
activ
ligas
preferenti
induc
tumour
cell
death
primari
acut
myeloid
leukaemia
cell
effect
also
studi
mous
model
leukaemia
reduc
tumour
weight
volum
studi
underlin
import
potenti
drug
target
leukaemia
possibl
cancer
especi
case
neoplast
cell
resist
treatment
proteasom
inhibitor
bortezomib
ref
furthermor
two
natur
product
identifi
inhibit
panepophenanthrin
isol
mushroom
panu
rudi
ref
himeic
acid
deriv
fungu
aspergillu
sp
ref
inhibit
ubiquitin
activ
vitro
unknown
mechan
recent
smallmolecul
inhibitor
enzym
also
discov
leucettamol
compound
isol
marin
spong
leucetta
aff
microrhaphi
identifi
novel
inhibitor
interact
therebi
block
format
complex
ref
also
alloster
inhibitor
human
ligas
found
smallmolecul
screen
inhibitor
ubiquityl
shown
interfer
prolifer
human
cancer
cell
line
ref
gener
target
conjug
enzym
sever
pathway
depend
ubiquityl
dna
repair
endocytosi
inhibit
time
potenti
contribut
increas
nonspecif
cytotox
therefor
therapeut
standpoint
use
ubiquitin
specif
inhibitor
current
await
addit
preclin
valid
advanc
clinic
studi
neural
precursor
cellexpress
development
ubiquitinlik
protein
highest
homolog
ubiquitin
conjug
substrat
neddyl
requir
activ
transfer
ref
primarili
function
regul
ubiquitin
ligas
modifi
member
cullin
famili
cullin
scaffold
compon
scf
ubiquitin
ligas
control
proteasom
degrad
protein
involv
cell
cycl
transcript
regul
signal
transduct
ref
neddyl
cullin
result
increas
ubiquityl
scf
substrat
protein
subsequ
proteasom
degrad
scf
ligas
promot
ubiquityl
protein
involv
inflamm
tumourigenesi
ref
ref
therefor
specif
inhibit
enzym
compon
neddyl
pathway
repres
altern
approach
target
up
cancer
treatment
fig
compound
smallmolecul
inhibitor
enzym
present
evalu
phase
clinic
trial
increas
apoptosi
sever
tumour
cell
line
murin
tumour
xenograft
consid
promis
drug
candid
myeloid
leukaemia
ref
contrast
proteasom
inhibitor
bortezomib
specif
inhibit
bulk
proteasom
degrad
ref
function
mechan
involv
format
coval
adduct
similar
first
intermedi
reaction
catalys
enzym
thu
effici
inhibit
enzym
ref
given
scf
ligas
repres
sever
hundr
known
ubiquitin
ligas
concern
inhibit
ligas
might
lead
seriou
side
effect
clinic
set
howev
impact
side
effect
must
taken
context
proteasom
inhibitor
shown
exhibit
accept
clinic
profil
treatment
cancer
yet
modul
stabil
mani
protein
rel
scf
ultim
evalu
successor
compound
clinic
set
determin
whether
strategi
therapeut
accept
approach
ubiquitin
system
ubiquitom
compar
wellcharacteris
kinom
spur
entir
array
novel
inhibitor
molecular
target
manipul
ubiquitin
ubiquitinlik
molecul
similarli
kinas
field
function
redund
structur
similar
activ
site
dub
divers
interact
domain
conjug
enzym
render
discoveri
specif
inhibitor
challeng
sever
novel
compound
promis
result
clinic
trial
proteasom
inhibitor
carfizomib
phase
iii
phase
phase
nae
inhibitor
phase
aml
solid
tumour
thalidomid
clinic
use
mani
year
recent
identifi
ligas
inhibitor
also
sever
ligas
inhibitor
compound
prove
success
preclin
stage
gener
remain
determin
whether
small
molecul
requir
specif
target
one
molecul
clinic
use
whether
manner
similar
medic
relev
kinas
inhibitor
molecul
broader
specif
subfamili
enzym
might
exhibit
clinic
efficaci
clearli
emerg
new
inhibitor
direct
up
compon
supplement
activ
kinas
inhibitor
cytotox
agent
compound
predict
ultim
combinatori
use
drug
hold
greatest
promis
futur
therapi
cancer
neurodegen
disord
infecti
diseas
diseas
patholog
highli
complex
substanti
differ
occur
individu
broaden
arsen
smallmolecul
compound
includ
drug
target
compon
up
might
provid
framework
individualis
drug
regimen
part
trend
toward
personalis
medicin
gener
understand
precis
role
ligas
dub
compon
up
diseas
process
establish
correl
dysfunct
properti
diseas
pathologydevelop
promis
lead
compound
effect
inhibitor
greater
potencywherea
mani
smallmolecul
compound
show
antiprolif
activ
tumour
cell
line
less
clear
translat
inhibit
tumour
growth
vivo
without
affect
normal
cell
distinguish
two
scenario
drive
select
develop
effect
compound
futurei
realli
necessari
chemic
target
one
enzym
optim
interfer
diseas
progress
mani
diseas
particular
cancer
exert
aberr
sever
biochem
pathway
discoveri
pharmacolog
target
abnorm
function
network
necessari
better
treatment
futur
